Abstract: Objective To explore the efficacy，mechanism and safety of silibinin combined with Ruangan pills（a Chinese herbal preparation）in the treatment of schistosomiasis liver fibrosis. Methods A total of 200 patients with schistosomiasis liver fibrosis were randomly divided into a control group and a treatment group，and 100 patients in each group were respectively admin? istered with oral silibinin alone and oral silibinin combined with Ruangan pills，respectively. The curative effects in the two groups were evaluated in 3 months，6 months，9 months and 12 months respectively. Results The common five clinical symptoms of schistosomiasis liver fibrosis patients significantly relieved in the treatment group 12 months after the therapy，and the total effi? ciency reached more than 75%，which were significantly higher than that in the control group. In the treatment group and the con? trol group，there was no improvement in the liver B ultrasonic classification 3 months and 6 months after the therapy（P > 0.05）； however，in 9 months and 12 months，the liver B ultrasonic classification in the treatment group was better than that in the control group（P < 0.05，P < 0.01，respectively） . For the four serum indexes of liver fibrosis，there was no significant differences between the two groups in 3 months，however，in 6 months，9 months，and 12 months，there was a significant improvement in the treat? ment group compared with the control group. There were no obviously adverse effects in two groups. Conclusion Silibinin com? bined with Ruangan pills has a better curative effect in the treatment of schistosomiasis liver fibrosis.

Key words: Schistosomiasis； Liver fibrosis；Ruangan pill；Silibinin

摘要： 目的 目的 探讨水飞蓟宾联合软肝丸治疗血吸虫病肝纤维化的疗效、 机制及安全性。方法 方法 将200例血吸虫病肝纤 维化患者随机分为对照组和治疗组， 每组100例， 分别采用水飞蓟宾 （对照组）、 水飞蓟宾联合软肝丸口服 （治疗组）， 于治疗 3、 6、 9个月和12个月， 比较观察2组患者的临床效果。结果 结果 治疗12个月后， 患者5项临床症状治疗组明显减轻， 总有效 率均达75% 以上， 均显著高于对照组。肝脏B超分级治疗组与对照组比较， 3、 6个月时无改善 （P均＞0.05）， 9、 12个月时， 治疗组好于对照组 （P均＜0.05）。治疗组治疗3、 6个月时均无改善 （P均＞0.05）， 9、 12个月时较6个月时有改善 （P均＜ 0.05）。血清肝纤维化四项， 治疗3个月时， 治疗组与对照组差异无统计学意义 （P＞0.05）； 6、 9、 12个月时， 差异均有统计学 意义 （P均＜0.05）； 治疗组治疗3、 6个月时比较， 差异无统计学意义 （P＞0.05）， 9、 12个月时均低于6个月时 （P均＜0.05）。 治疗过程中未出现明显不良反应。结论 结论 水飞蓟宾联合软肝丸有较好的抗血吸虫病肝纤维化的作用。

关键词: 血吸虫病； 肝纤维化； 软肝丸； 水飞蓟宾